Results 111 to 120 of about 169,027 (313)

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

Alzheimer’s Research & Therapy, 2018
Background We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patients with mild-to-moderate Alzheimer ...
Stephen Salloway, Lee A. Honigberg, William Cho, Michael Ward, Michel Friesenhahn, Flavia Brunstein, Angelica Quartino, David Clayton, Deborah Mortensen, Tobias Bittner, Carole Ho, Christina Rabe, Stephen P. Schauer, Kristin R. Wildsmith, Reina N. Fuji, Shehnaaz Suliman, Eric M. Reiman, Kewei Chen, Robert Paul   +18 more
doaj   +1 more source

Use of single-chain antibody derivatives for targeted drug delivery [PDF]

, 2016
Single-chain antibodies (scFvs), which contain only the variable domains of full-length antibodies, are relatively small molecules that can be used for selective drug delivery.
Ahmadzadeh, V., Erfani-Moghadam, V., Jaliani, H.Z., Khalili, M., Safdari, Y., Zarei, V.   +5 more
core   +1 more source

Outcome of Patients With Lupus Nephritis Treated With an Anti‐CD40 Monoclonal Antibody According to Kidney Biopsy Features

Arthritis &Rheumatology, EarlyView.
Objective A phase 2 trial tested different doses of the anti‐CD40 monoclonal antibody BI 655064 as an add‐on therapy to the standard of care in patients with class III or IV lupus nephritis (LN) with active disease. A post hoc analysis showed a potential benefit of the higher tested doses (180 and 240 mg) versus a low dose (120 mg) or placebo.
Martina Uzzo, Helmut Schumacher, Juergen Steffgen, Simone Deutschel, David Jayne, Ingeborg Bajema   +5 more
wiley   +1 more source

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors

CPT: Pharmacometrics &Systems Pharmacology, Volume 12, Issue 1, Page 95-109, January 2023., 2023
Abstract Tislelizumab, a humanized immunoglobulin G4 monoclonal antibody, is a programmed cell death protein 1 (PD‐1) inhibitor designed to minimize Fc gamma receptor binding on macrophages to limit antibody‐dependent phagocytosis, a potential mechanism of resistance to anti–PD‐1 therapy.
Nageshwar Budha, Chi‐Yuan Wu, Zhiyu Tang, Tian Yu, Lucy Liu, Fengyan Xu, Yuying Gao, Ruiying Li, Qiuyang Zhang, Ya Wan, Srikumar Sahasranaman   +10 more
wiley   +1 more source

Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rγc KO. NOD)

Human Vaccines & Immunotherapeutics, 2018
Pandemic outbreaks of influenza type A viruses have resulted in numerous fatalities around the globe. Since the conventional influenza vaccines (CIV) provide less than 20% protection for individuals with weak immune system, it has been considered that ...
Mirian Mendoza, Angela Ballesteros, Qi Qiu, Luis Pow Sang, Soumya Shashikumar, Sofia Casares, Teodor-D. Brumeanu   +6 more
doaj   +1 more source

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. [PDF]

, 2018
Polyneuropathy with immunoglobulin M (IgM) monoclonal gammopathy is the most common paraproteinemic neuropathy, comprising a clinicopathologically and immunologically distinct entity.
Dalakas, Marinos
core   +2 more sources

Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy

Arthritis &Rheumatology, EarlyView.
Objective The objective was to report the safety and efficacy of an anti‐IFNAR1 antibody (anifrolumab) in a patient with STING‐associated vasculopathy with onset in infancy (SAVI) who presented with vasculitic ulcers and systemic inflammation refractory to JAK inhibition (JAKi) and to the interferon‐β–neutralizing monoclonal antibody dazukibart ...
Sara Alehashemi, Bjoern Buehring, Adriana A. de Jesus, Sachin Gaurav, Andre Rastegar, Alexi Baumgardner, Kip Friend, Oluwatobi T. Arisa, William D. Figg, Danielle Fink, Douglas B. Kuhns, Ben Colton, Cody J. Peer, Raphaela Goldbach‐Mansky   +13 more
wiley   +1 more source

Ricci Flow and Entropy Model for Avascular Tumor Growth and Decay Control [PDF]

arXiv, 2008
Prediction and control of cancer invasion is a vital problem in medical science. This paper proposes a modern geometric Ricci-flow and entropy based model for control of avascular multicellular tumor spheroid growth and decay. As a tumor growth/decay control tool, a monoclonal antibody therapy is proposed.
arxiv  

Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The phase 3 MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA.
Michael E. Wechsler, Jared Silver, Gerhard Wolff, Robert G. Price, Rejina Verghis, Peter F. Weller, Peter A. Merkel, Paneez Khoury, on behalf of the EGPA Mepolizumab Open‐Label Extension study group, Arnaud Bourdin, Pascal Chanez, Anoop Chauhan, Vincent Cottin, Gerald Gleich, Berhnard Hellmich, Tomonori Ishii, David Jayne, Jean‐Emmanuel Kahn, Peter Kern, Nader Khalidi, Ina Koetter, Carol Langford, Amy Markezich, Paul Monach, Shamsa Naveed, Peter Oelzner, Kenneth Pinna, Xavier Puechal, Emory H. Robinette, Florence Roufosse, Reinhard Voll, Andrew Schafer, Kaharu Sumino, Masami Taniguchi, Phillip Lieberman   +34 more
wiley   +1 more source

The receptor-toxin-antibody interaction: Mathematical model and numerical simulation [PDF]

arXiv, 2012
A reaction-diffusion model of receptor-toxin-antibody (RTA) interaction is studied numerically. The protective properties of an antibody against a given toxin are evaluated for a spherical cell placed into a toxin-antibody solution. The selection of parameters for numerical simulation approximately corresponds to the practically relevant values ...
arxiv